Guggenheim analyst Michael Schmidt lowered the firm’s price target on Genmab (GMAB) to $40 from $45 and keeps a Buy rating on the shares, citing lowered near-term Epkinly estimates.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GMAB:
- Genmab Discloses CFO Insider Share Sale Under EU Market Abuse Rules
- Genmab Expands Blood Cancer Pipeline With First-in-Human GEN3018 Trial
- Genmab Expands Oncology Pipeline With New First-in-Human GEN1079 Trial
- Genmab Calls March 19 AGM to Approve 2025 Results and Capital Reduction
- Genmab: Solid Royalties and Strategic Deals, But 2026 Data Risks Justify Maintaining a Hold at $32 Target